Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Retained Earnings (2018 - 2026)

Immunovant filings provide 8 years of Retained Earnings readings, the most recent being -$1.6 billion for Q4 2025.

  • Quarterly Retained Earnings fell 64533.24% to -$1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.6 billion through Dec 2025, down 64533.24% year-over-year, with the annual reading at $1.5 million for FY2025, 23.53% down from the prior year.
  • Retained Earnings hit -$1.6 billion in Q4 2025 for Immunovant, down from $1.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.5 million in Q4 2024 and bottomed at -$1.6 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$311.1 million, with a median of -$449000.0 recorded in 2021.
  • The largest annual shift saw Retained Earnings crashed 145067.03% in 2022 before it surged 513.17% in 2024.
  • Immunovant's Retained Earnings stood at -$308.2 million in 2021, then tumbled by 64.48% to -$506.9 million in 2022, then soared by 99.88% to -$600000.0 in 2023, then surged by 513.17% to $2.5 million in 2024, then plummeted by 64533.24% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Retained Earnings are -$1.6 billion (Q4 2025), $1.4 million (Q3 2025), and -$1.4 billion (Q2 2025).